Subscribe

  • How Can We Help You?

    Global Problem Solving from Covington: Deal with Complex Problems Anywhere in the World

Toro_Amy_1000x714_ENV

Amy L. Toro

Partner

San Francisco +1 415 591 7086

  • About
  • Representative Matters
  • Credentials
  • About

    Amy Toro advises both pharmaceutical and biotechnology companies regarding biologics, pharmaceuticals and devices, including in the digital health space. Amy works on all types of life sciences transactions, including major collaborations, licensing arrangements, clinical trial agreements, supply and distribution agreements, product development funding deals, and joint ventures and a variety of commercial agreements. She also works with her mergers and acquisition colleagues on product divestitures and asset transfers.

    She received her J.D. from the Boalt Hall School of Law, University of California, Berkeley in 1994, and a Ph.D. in Jurisprudence and Social Policy in 2000.

    Amy has clerked for the Hon. Stephen F. Williams of the U.S. Court of Appeals for the District of Columbia Circuit from 1996 to 1997.  She has also served as a visiting professor of law at Northwestern University School of Law and at the University of California, Davis.

    She is admitted to the California Bar.

    Areas of Expertise

  • Practices and Industries
  • Representative Matters
    • Representing a start-up company in possible spin-out license from a large pharmaceutical company.
    • Representing Amyris, Inc., a biotechnology company focused on biofuels, in joint venture and other commercial transactions with Total and other strategic collaboration partners.
    • Represented Gilead Sciences, Inc., in negotiating multiple agreements with Tibotec Pharmaceuticals for the development and commercialization of three different combination products for the treatment of HIV.
    • Represented Sanofi U.S. in multiple license and collaboration agreements, including an out-license agreement of a nasal inhalant product for the treatment of allergies.
    • Represented AstraZeneca in negotiating an in-license agreement with Nektar Therapeutics to develop and commercialize a pegylated opioid product, including for the treatment of opioid-induced constipation.
    • Represented Lilly in negotiating certain manufacturing arrangements relating to its agreement with Evonik for the sale of its Tippecanoe facility.

    • Represented Boehringer-Ingelheim in negotiating certain manufacturing arrangements relating to its purchase of animal health assets from Pfizer, Inc..
    • Advised Novartis regarding a vaccine technology transfer agreement with a government-owned Brazilian pharmaceutical company. 
    • Represented Gilead Sciences, Inc., in negotiation of a various agreements with BMS and Merck relating to the commercialization of Atripla, a triple combination product for the treatment of HIV.

    Areas of Expertise

  • Credentials
    Education
    • University of California, Berkeley, Ph.D., 2000
    • University of California, Berkeley School of Law, J.D., 1994
    • University of Virginia, B.A., 1988
    Bar Admissions
    • California
    Judicial Clerkship
    • Hon. Stephen F. Williams, U.S. Court of Appeals, District of Columbia Circuit, 1996 - 1997
    Accolades
    • Law360, Life Sciences MVP (2022)
    • Daily Journal, "Top Health Care Lawyers" (2020-2022)
    • Legal 500 US, Intellectual Property - Patents - Licensing (2017) and Media, Technology and Telecoms - Technology - Transactions (2015, 2017) 
    • Chambers USA, Life Sciences: Corporate/Commercial (2011-2014; 2019-2023)
    • The Daily Journal, Top Women Lawyers (2013)
    • LMG Life Sciences, "Life Science Star" (2013)
    • IAM Patent 1000 - The World’s Leading Patent Practitioners (2015-2016)
    • Northern California Rising Stars, Intellectual Property (2009-2010)
    Previous Experience
    • Northwestern University School of Law, Visiting Assistant Professor of Law (1998)
    • University of California, Davis, Visiting Professor (1999)

    Areas of Expertise

Life Sciences DNA Test Tubes-transform

Insights February 2023

Synthetic Royalty and Drug Development Financing Study

News and Insights

Events